Every 8-K that Predictive Oncology Inc. (POAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow POAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full POAI filings page.
Axe Compute Inc. is updating its risk disclosures to reflect a strategic shift from an asset-light model to purchasing, owning, and operating GPU computing infrastructure in dedicated data centers. This model is capital-intensive and will require substantial and growing funding from customer deposits, operations, and equity or debt financing.
The company highlights risks around rapid GPU obsolescence, potential impairment charges, concentration of revenue in a few large contracts, and dependence on reliable data center power and cooling, including 4.8 megawatts of committed power for its largest deployment. It also notes reliance on NVIDIA and complex global supply chains, exposure to export controls and geopolitical tensions, and execution risk for a targeted third-quarter 2026 deployment tied to a large, approximately $260 million enterprise engagement.
Additional risks include possible underutilization of purpose-built capacity, plans to incur secured or asset-backed indebtedness, limited operating history with owned GPU infrastructure, sensitivity to volatile energy costs and new environmental rules, cybersecurity and operational failures, and heightened liquidity dependence, including on ATH digital asset holdings.
Axe Compute Inc. filed an 8-K describing a new prospectus supplement tied to its existing Form S-3 shelf and at-the-market stock offering program with H.C. Wainwright & Co. as sales agent. Following this supplement, the aggregate amount of shares that are available for sale under the ATM program is $100,000,000.
The company notes it is no longer subject to the offering limitations of General Instruction I.B.6 of Form S-3 and that, during the 12 calendar months up to and including the prospectus supplement date, it sold securities with an aggregate market value of approximately $12.7 million under this framework. A legal opinion from Lucosky Brookman LLP covering the ATM shares is filed as Exhibit 5.1.
Axe Compute Inc. filed a current report describing plans for its upcoming first-quarter 2026 financial results release. The company will issue its Q1 2026 financial results for the quarter ended March 31, 2026 before market open on May 18, 2026, and will host a conference call and webcast at 8:30 a.m. Eastern Time the same day to review the results. Dial-in, meeting ID, passcode, and webcast registration details are provided, and a replay will be available on the investor relations website. No financial results are included in this report; it mainly alerts investors to how and when they can access the forthcoming earnings information.
Axe Compute Inc. entered into a 36‑month enterprise infrastructure contract with an aggregate value of approximately $260 million, described as the largest enterprise engagement in its history. The deal covers a dedicated cluster of 2,304 NVIDIA B300 GPUs plus AI‑focused high‑speed storage in a single U.S. Tier 3 data center.
The infrastructure is purpose-built for large-scale AI model training, fine-tuning, inference, and data processing, backed by 4.8 megawatts of N+1 redundant power and enterprise-grade service levels. Deployment is targeted to commence in Q3 2026, with payments structured via deposit, prepayment, and monthly take‑or‑pay charges, and options to renew beyond the initial term.
Axe Compute Inc. appointed Kyle Okamoto as President effective April 1, 2026, under an employment agreement providing a $360,000 base salary, a target annual bonus of $500,000, and stock options for 300,000 shares at a $1.62 exercise price, vesting over four years. The company also reported signing about $12 million in executed agreements over the last 30 days, expected to generate an estimated $835,000 in monthly income upon deployment entering Q2 2026, or roughly $7.5 million of estimated income from signed contracts in 2026 across more than 20 enterprise customers and 30 active deployments.
Axe Compute Inc. reported full-year 2025 results that reflect a major strategic pivot to AI GPU infrastructure and a digital asset treasury model, alongside a very large accounting loss. Revenue was modest at $125,284, all from the legacy Drug Discovery Services segment, with no compute revenue yet recognized.
The company recorded a loss from continuing operations of $232.9 million, driven mainly by $152.5 million in unrealized losses on ATH digital assets and a $52.7 million loss on derivative instruments, plus higher operating expenses as it repositioned the business. Despite this, Axe raised $343.5 million through October 2025 PIPE transactions and held $10.8 million in cash and $24.4 million of unlocked ATH tokens as of December 31, 2025.
These transactions transformed the balance sheet from a stockholders’ deficit to $47.7 million in equity and funded a Strategic Compute Reserve tied to the Aethir ATH token. The company established marketplace access to over 435,000 GPUs globally and plans to prioritize generating initial compute revenue, staking ATH for yield, and completing a review of strategic alternatives for its Helomics legacy business in 2026.
Axe Compute Inc. appointed Dr. Theodore Zhu and Mr. Thorston Dirks to its board of directors. Dr. Zhu is Founder and Chairman of Iotelligent Technology, with prior leadership roles at Celestial Semiconductor, Jazz Semiconductor, BitShield, Conexant, Honeywell, Motorola, and Brown University.
Mr. Dirks brings nineteen years of board-level experience and about fifteen years as Chief Executive Officer in telecommunications and aviation, including leading E-Plus Group, Telefónica Deutschland, and Deutsche Glasfaser, and serving on the executive boards of Deutsche Lufthansa AG, KPN N.V., and Telefónica S.A. Their director compensation will align with the company’s existing director compensation program.
Axe Compute Inc. is undergoing a major leadership transition. The board terminated Chief Executive Officer Raymond F. Vennare without cause, effective February 9, 2026, and he resigned as chairman and director. He will receive $575,000 in severance, a $287,500 2025 bonus, and a healthcare-related lump-sum payment under a separation agreement.
The company appointed director Chuck Nuzum as chairman and named Christopher Miglino as the new CEO and a director, effective the same date. Miglino brings more than 25 years of experience leading public and private technology and fintech businesses and has been involved in structuring Axe Compute’s digital asset treasury and AI compute strategy. His employment agreement provides a $575,000 annual base salary, bonus eligibility, and an inducement stock option grant for 500,000 shares that vest over three years. A related press release highlights the company’s focus on decentralized GPU compute, AI infrastructure, and a treasury-backed compute strategy.
Predictive Oncology Inc. is changing its corporate name to Axe Compute Inc., effective December 11, 2025. The change was approved by the board of directors under Delaware law and did not require a stockholder vote.
In connection with the name change, the company adopted Third Amended and Restated Bylaws that update the corporate name and integrate prior amendments, with no other substantive changes. The company’s common stock is expected to begin trading on Nasdaq under the new ticker symbol AGPU on or about December 12, 2025. Existing stock certificates remain valid and do not need to be exchanged.
Predictive Oncology Inc. reported results from its 2025 annual stockholder meeting. Stockholders approved an amendment to the 2024 Equity Incentive Plan that increases the shares available for issuance by 1,000,000 shares, expanding the pool for employee and director equity awards. They also elected two Class I directors to serve until the 2028 annual meeting and ratified KPMG LLP as independent auditor for the fiscal year ending December 31, 2025.
Stockholders approved the issuance of 14,903,393 shares of common stock upon exercise of pre-funded warrants, as required by Nasdaq Listing Rule 5635(a). They further supported, on a non-binding advisory basis, the compensation of the company’s named executive officers. As of the record date for the meeting, there were 3,501,430 shares of common stock entitled to vote.
Predictive Oncology Inc. (POAI) reports that it believes it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company cites stockholders’ equity in excess of $2.5 million following the closing of two private investment in public equity (PIPE) transactions on October 7, 2025. These PIPE deals provided an aggregate of approximately $343.5 million, including about $50.8 million in cash and approximately $292.7 million in notional value of in-kind contributions of certain crypto assets, which the company states represent a discounted value of about $173.3 million. This capital and asset infusion is the basis for the company’s view that it satisfies Nasdaq Listing Rule 5550(b)(1).
Predictive Oncology Inc. announced that it scheduled a conference call and webcast at 9:00 a.m. Eastern Time on November 17, 2025 to discuss its financial results for the third quarter ended September 30, 2025 and to provide an update on its digital asset strategy. The company prepared an investor presentation for this event, which is available on its investor relations page and is furnished as Exhibit 99.1. The furnished materials are provided under Regulation FD and are not treated as filed for liability purposes under the securities laws unless specifically incorporated by reference in another filing.
Predictive Oncology Inc. filed a prospectus supplement to its existing S-3 ATM program, updating the amount it may sell under General Instruction I.B.6. As of October 29, 2025, the company may offer and sell common stock with an aggregate offering price of up to $18,330,000 through H.C. Wainwright & Co. as sales agent.
The filing notes the I.B.6 framework, allowing primary offerings up to one-third of public float and removal of this limit if public float exceeds $75.0 million. It also states that approximately $2,417,337 of securities were sold under I.B.6 during the prior 12 months.
Predictive Oncology set its 2025 annual meeting for November 25, 2025, in Pittsburgh at DLA Piper LLP (US). Stockholders of record on October 24, 2025 will be entitled to vote.
Stockholder proposals and proxy access requests must be received by October 26, 2025. The company expects to mail definitive proxy materials on or about November 3, 2025 and may supplement those materials, and if necessary postpone the meeting, to address any timely proposals.
Predictive Oncology Inc. filed an 8-K describing a press release issued on October 8, 2025. The release announced the closing of two private placements on October 7, 2025 and the company’s adoption of a digital asset treasury strategy, signaling a change in how it may hold part of its treasury assets. The press release is furnished under Regulation FD and attached as Exhibit 99.1, with most of its content (excluding the fifth and sixth paragraphs) also treated as an “Other Event” disclosure.
Predictive Oncology Inc. disclosed material transactions tied to private placements that include cash and cryptocurrency investments subject to customary closing conditions. The company agreed to issue placement agent warrants to purchase approximately 3.3 million shares exercisable at $0.7751 for five years and to pay a 5% cash fee to the placement agent for gross cash proceeds (excluding digital-asset proceeds). Strategic advisor warrants equal to approximately 20.3 million shares (about 7% of the securities sold) will be issued, exercisable at $0.7751 for five years and carrying a beneficial ownership cap of 4.99% (or optionally 9.99%). A Side Letter with DCI Foundation requires DCI to cure issues with locked crypto within five business days and to deliver an additional 20% of ATH tokens bought on the open market within 30 days of each purchase. The company amended bylaws effective September 26, 2025 to cap the board at seven directors. Various form agreements and exhibits were filed.
Predictive Oncology Inc. reported that it has issued a press release announcing two private placements and the adoption of a digital asset treasury strategy. The company states that it plans to maintain its existing lines of business while also pursuing this new approach to managing part of its treasury in digital assets. These updates are provided for information purposes under Regulation FD and, as described, are not being treated as filed financial information under securities law.
Predictive Oncology, Inc. filed a Form 8-K reporting a material event that includes a Certificate of Amendment to its certificate of incorporation and an attached press release dated September 25, 2025. The filing lists several numeric items (including share or schedule figures) and includes an Inline XBRL cover file. The report is signed by Josh Blacher, identified as Interim Chief Financial Officer, indicating an interim finance leader is in place. The 8-K supplies disclosure documents but does not include earnings figures, transaction details, or explanatory narrative about the amendment within the provided text.
Predictive Oncology Inc. entered into a Securities Purchase Agreement with an accredited investor for a private placement of 543,544 shares of common stock at $0.76 per share, for gross proceeds of approximately $413,093. The deal closed on August 26, 2025.
The company agreed to limits on issuing additional common stock or equivalents and granted the investor a 100% participation right in future equity offerings through October 31, 2025. It plans to use net proceeds for working capital and general corporate purposes and must file a resale registration statement within 90 days, relying on Section 4(a)(2) and Rule 506(b) exemptions.
Predictive Oncology Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company used this filing to formally furnish the press release, which is included as Exhibit 99.1. This gives investors access to the detailed quarterly performance information through the attached exhibit rather than within the body of the report.